The Asia Pacific Renal Denervation Market is expected to witness market growth of 38.8% CAGR during the forecast period (2022-2028).
Renal denervation has been a proposed technique to aid in the treatment of RH since it was initially utilized when hypertension remains uncontrolled after changes in lifestyle and antihypertensive medicines. Numerous research and randomized control trials have been conducted since then to assess the efficacy of this method in treating RH, with mixed results.
Because renal denervation reduces whole-body sympathetic nerve activity, clinical conditions characterized by sympathetic nervous system activation, such as metabolic abnormalities and sleep apnea, heart failure, chronic kidney disease, and arrhythmias, could be new indications for the procedure. Various small clinical studies have demonstrated the potential advantage of renal denervation in these clinical settings, and major clinical trials are required to verify this notion. Catheter-based RDN is a potential and innovative therapeutic technique, and more research is needed to see if it can be used to manage patients with resistant hypertension as well as mild to moderate hypertension.
There are numerous unmet medical requirements connected to hypertension, as well as increased awareness of advanced technologies such as renal denervation systems and the high prevalence of resistant hypertension, which is creating demand for renal denervation is expected to surge across the region. Blood pressure measurement becomes simple and painless with the advent of renal denervation. Systolic indicates blood vessel pressure while the heart contracts or beats, and diastolic represents blood vessel pressure when the heart rests between beats. When measured twice on varying days, hypertension is diagnosed when the systolic blood pressure is 140 mmHg on both measures and the diastolic blood pressure is 90 mmHg on both readings. To decrease hypertension and its problems, it is critical to know one's blood pressure level by checking it often, adopting a healthy lifestyle, and sticking to the prescribed therapy.
The China Market dominated the Asia Pacific Renal Denervation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $109.8 million by 2028. The Japan Market is experiencing a CAGR of 38% during (2022-2028). Additionally, The India Market is expected to showcase a CAGR of 39.7% during (2022-2028).
Based on Technology, the Market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. Based on End User, the Market is segmented into Hospitals, Specialty Clinics, and Others. Based on Product Type, the Market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.
By Technology
By Country
Renal denervation has been a proposed technique to aid in the treatment of RH since it was initially utilized when hypertension remains uncontrolled after changes in lifestyle and antihypertensive medicines. Numerous research and randomized control trials have been conducted since then to assess the efficacy of this method in treating RH, with mixed results.
Because renal denervation reduces whole-body sympathetic nerve activity, clinical conditions characterized by sympathetic nervous system activation, such as metabolic abnormalities and sleep apnea, heart failure, chronic kidney disease, and arrhythmias, could be new indications for the procedure. Various small clinical studies have demonstrated the potential advantage of renal denervation in these clinical settings, and major clinical trials are required to verify this notion. Catheter-based RDN is a potential and innovative therapeutic technique, and more research is needed to see if it can be used to manage patients with resistant hypertension as well as mild to moderate hypertension.
There are numerous unmet medical requirements connected to hypertension, as well as increased awareness of advanced technologies such as renal denervation systems and the high prevalence of resistant hypertension, which is creating demand for renal denervation is expected to surge across the region. Blood pressure measurement becomes simple and painless with the advent of renal denervation. Systolic indicates blood vessel pressure while the heart contracts or beats, and diastolic represents blood vessel pressure when the heart rests between beats. When measured twice on varying days, hypertension is diagnosed when the systolic blood pressure is 140 mmHg on both measures and the diastolic blood pressure is 90 mmHg on both readings. To decrease hypertension and its problems, it is critical to know one's blood pressure level by checking it often, adopting a healthy lifestyle, and sticking to the prescribed therapy.
The China Market dominated the Asia Pacific Renal Denervation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $109.8 million by 2028. The Japan Market is experiencing a CAGR of 38% during (2022-2028). Additionally, The India Market is expected to showcase a CAGR of 39.7% during (2022-2028).
Based on Technology, the Market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. Based on End User, the Market is segmented into Hospitals, Specialty Clinics, and Others. Based on Product Type, the Market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Radiofrequency
- Ultrasound
- Micro-Infusion
- Hospitals
- Specialty Clinics
- Others
- Symplicity
- Enlightn
- Vessix
- Paradise
- Iberis
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic PLC
- Ablative Solutions, Inc.
- Mercator MedSystems, Inc.
- ReCor Medical, Inc.
- Renal Dynamics Limited
- Johnson & Johnson
- Terumo Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Renal Denervation Market by Technology
Chapter 4. Asia Pacific Renal Denervation Market by End User
Chapter 5. Asia Pacific Renal Denervation Market by Product Type
Chapter 6. Asia Pacific Renal Denervation Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic PLC
- Ablative Solutions, Inc.
- Mercator MedSystems, Inc.
- ReCor Medical, Inc.
- Renal Dynamics Limited
- Johnson & Johnson
- Terumo Corporation
Methodology
LOADING...
